Alpha-7 Nicotinic Receptor Allosteric Modulators
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for neurodegenerative and neuropsychiatric diseases, such as Alzheimer's and schizophrenia, have limitations in effectively targeting alpha 7 nicotinic acetylcholine receptors (α7nAChRs) for cognitive enhancement and neuroprotection, particularly in preserving neurotransmission integrity and addressing inflammatory responses.
Innovation Solution
Development of new chemical compounds, specifically those of formulas (I), (Ia), and (II), which are designed to positively modulate α7nAChRs, offering selective allosteric modulation that enhances acetylcholine sensitivity and neuroprotective effects while minimizing desensitization kinetics, thereby treating cognitive deficits and inflammatory diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If selective positive allosteric modulation of α7nAChR is used to enhance acetylcholine sensitivity, then cognitive function and neuroprotection are improved, but desensitization kinetics are affected which may limit duration of action
Solution Approach 1:
The patent applies parameter changes by developing compounds that selectively modulate specific parameters of α7nAChR function (peak current, desensitization kinetics) while preserving others. The compounds achieve this by binding to the allosteric site and inducing conformational changes that enhance acetylcholine sensitivity without permanently altering receptor structure, thus maintaining both improved sensitivity and appropriate duration of action.
2Reliability
If Type II modulators are used to modify desensitization profile, then agonist sensitivity is enhanced, but current amplitude control becomes more complex
Solution Approach 1:
The patent applies local quality by designing compounds that target specific local features of the α7nAChR allosteric site. The molecular structure is optimized to interact with particular amino acid residues and structural elements that are responsible for desensitization kinetics, thereby selectively modifying this local property without broadly affecting other aspects of receptor function such as peak current amplitude.
3Reliability
If existing PAMs like PNU-120596 are used to enhance acetylcholine sensitivity, then neuroprotective effects are improved, but profound effects on receptor desensitization occur which may affect neurotransmission integrity
Solution Approach 1:
The patent applies dynamics by developing compounds that induce reversible, transient conformational changes in the α7nAChR rather than stable, permanent modifications. The allosteric modulation dynamically adjusts receptor responsiveness to acetylcholine in real-time, enhancing neuroprotective signaling while allowing the receptor to return to its baseline state, thus preserving neurotransmission integrity.
Data Source
AI summary
The present invention relates to compounds of formula (I) with the substituents as described within the specification. The compounds are useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (a7nAChR). The invention also relates to the use of these compounds in the treatment or prevention of a broad range of diseases in which the positive modulation of a7nAChR is advantageous, including neurodegenerative and neuropsychiatric diseases and also inflammatory diseases.